Markets stall under threat of government shutdown >>> READ MORE

5 Best and Worst S&P 500 Stocks of 2011

A look at the biggest stock duds and market heroes of the year

      View All  

#3 Best: Biogen Idec, +73.7%

Biogen BIIBBiotechnology firm Biogen Idec (NASDAQ:BIIB) makes several high-profile therapies, including Avonex and Tysabri, which are used for the treatment of relapsing multiple sclerosis, and Rituxan for treating non-Hodgkin’s lymphoma. Shares of the biotech winner are up 73.7% in 2011, and that’s proved to be potent fiscal therapy for shareholders.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC